NASDAQ: ASND - Ascendis Pharma A/S

Yield per half year: +7.53%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Ascendis Pharma A/S

Extended chart Simple chart
Financial Markets by TradingView

About Ascendis Pharma A/S

Ascendis Pharma A / S, биофармацевтическая компания, разрабатывает терапевтические препараты для неудовлетворенных медицинских потребностей. Компания разрабатывает гормон роста TransCon, который завершил III фазу клинических испытаний дефицита гормона роста. Он также разрабатывает паратиреоидный гормон TransCon для лечения гипопаратиреоза взрослых; и TransCon CNP для ахондроплазии.

more details
Кроме того, компания разрабатывает доклинические исследования в области онкологии для потенциальных кандидатов на продукты и оценивает системные и локализованные системы доставки с использованием своих технологий TransCon. Компания была зарегистрирована в 2006 году, ее штаб-квартира находится в Хеллерупе, Дания.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2015-01-28
ISIN US04351P1012
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета eur
Сайт https://ascendispharma.com
Цена ао 158.45
Change price per day: -1.61% (161.04)
Change price per week: -4.58% (166.05)
Change price per month: +4.89% (151.06)
Change price per 3 month: +14.17% (138.79)
Change price per half year: +7.53% (147.36)
Change price per year: +4.82% (151.17)
Change price per 3 year: +34.72% (117.61)
Change price per 5 year: +44.94% (109.32)
Change price per year to date: +22.01% (129.87)
All parameters

Underestimation

Title Value Grade
P/S 20.68 1
P/BV -71.14 0
P/E 0 0
EV/EBITDA -26.95 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -37.71 0
ROE, % 300.78 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -2.95 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 5129.99 10
Yield Ebitda, % -11.82 0
Yield EPS, % -19.99 0
Total: 2.2
More

Institutions Volume Share, %
Artisan Partners Limited Partnership 6 9.74
FMR, LLC 5 8.48
Westfield Capital Management Co LP 4 7
Avoro Capital Advisors LLC 4 6.81
Janus Henderson Group PLC 4 6.47
Wellington Management Group, LLP 3 4.72
T. Rowe Price Investment Management, Inc. 3 4.41
Capital International Investors 2 3.76
Franklin Resources, Inc. 2 3.4
Price (T.Rowe) Associates Inc 2 3.06

ETFShare, %Profitability for 1 year, %Dividends, %
Harbor Disruptive Innovation ETF 1.94674 29.05 0.39896
Future Tech ETF 0.85005 426.34 0.8416
Principal Healthcare Innovators ETF 0.85005 618.5 0.8416
1.22357.960.69



Head Job title Payment Year of birth
Mr. Jan Moller Mikkelsen President, CEO, Member of Executive Board & Executive Director N/A 1960 (65 years)
Mr. Michael Wolff Jensen L.L.M. Executive VP, Chief Legal Officer & Member of the Executive Board N/A 1971 (54 years)
Mr. Scott T. Smith CFO, Executive VP & Member of Executive Board N/A 1974 (51 year)
Ms. Lotte Sonderbjerg Executive VP, Chief Administrative Officer & Member of the Executive Board N/A 1961 (64 years)
Mr. Flemming Steen Jensen Executive Vice President of Product Supply & Quality N/A 1961 (64 years)
Mr. Timothy J. Lee Senior Director of Investor Relations N/A
Dr. Kennett Sprogoe Ph.D. Executive VP and Head of Research & Product Development N/A 1979 (46 years)
Mr. Mads Bodenhoff Senior VP of Finance & Principal Accounting Officer N/A
Dr. Stina Singel M.D., Ph.D. Executive VP & Head of Clinical Development for Oncology N/A 1974 (51 year)
Mr. Joseph Kelly Head of U.S. Commercial of Endocrinology N/A 1969 (56 years)

Address: Denmark, Hellerup, Tuborg Boulevard 12 - open in Google maps, open in Yandex maps
Website: https://ascendispharma.com